Mankind Pharma invests in UK-based cancer treatment focused startup Actimed

Delhi-based Mankind Pharma has invested in a clinical stage specialty pharmaceutical company, Actimed Therapeutics, UK, which is focused on bringing innovation to the treatment of cancer cachexia, an unmet medical need for cancer patients, and other muscle wasting disorders. Following the investment, Atish Majumdar, President (Sales & Marketing) of Mankind Pharma joins Actimed Therapeutics as a member of its Board of Directors. Mankind's investment helped Actimed - which is led by its CEO, Robin Bhattacherjee - close its second and final tranche of seed financing. Actimed is developing its lead asset S-pindolol for the treatment of cancer cachexia and has successfully completed a pharmacokinetic/pharmacodynamic (PK/PD) study for the drug which met all pre-defined objectives.